UNRIF yields 217.86% · JNJ yields 2.13%● Live data
📍 UNRIF pulled ahead of the other in Year 1
Combined, UNRIF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of UNRIF + JNJ for your $10,000?
United Company RUSAL, International Public Joint-Stock Company produces and sells aluminum and related products. It operates through four segments: Aluminium, Alumina, Energy, and Mining and Metals. The company is involved in the mining and refining of bauxite and nepheline ore into alumina; the smelting of primary aluminum from alumina; and the fabrication of aluminum and aluminum alloys into semi-fabricated and finished products. Its products include primary aluminum, billets, rolling slabs, primary foundry alloys, wire rods, high-purity aluminum, foil and packaging products, aluminum wheels and powders, alumina and bauxite products, corundum products, and gallium and silicon products, as well as aluminum anodes for cathodic protection. The company is also involved in the mining and sale of coal; generation and transmission of electricity produced from various sources; and trading businesses. In addition, it offers repair and maintenance, and finance services. The company sells its products primarily in Europe, Russia, other countries of the Commonwealth of Independent States, Asia, and North and South America. The company was founded in 2000 and is based in Kaliningrad, Russia. United Company RUSAL, International Public Joint-Stock Company is a subsidiary of En+ GROUP International public joint-stock company.
Full UNRIF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.